Form 4 Filing for Rajeev Dadoo

On June 24, 2026, Rajeev Dadoo, a director at ARS Pharmaceuticals, Inc. (SPRY), acquired 30,000 stock options. These options, which allow the purchase of common stock, have an exercise price of $10.54 and expire on June 23, 2036. The shares subject to the option will vest in full on the earlier of June 24, 2027, or the date of the Issuer's 2027 annual meeting of stockholders. Mr. Dadoo acquired these options under a direct ownership nature. The transaction was reported on a Form 4 filing dated June 26, 2026.